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Abstract
Background: Diet plays a role on the development of the immune system, and polyunsaturated fatty acids can
modulate the expression of a variety of genes. Human milk contains conjugated linoleic acid (CLA), a fatty acid
that seems to contribute to immune development. Indeed, recent studies carried out in our group in suckling
animals have shown that the immune function is enhanced after feeding them with an 80:20 isomer mix
composed of c9,t11 and t10,c12 CLA. However, little work has been done on the effects of CLA on gene
expression, and even less regarding immune system development in early life.
Results: The expression profile of mesenteric lymph nodes from animals supplemented with CLA during gestation
and suckling through dam’s milk (Group A) or by oral gavage (Group B), supplemented just during suckling (Group
C) and control animals (Group D) was determined with the aid of the specific GeneChip
® Rat Genome 230 2.0
(Affymettrix). Bioinformatics analyses were performed using the GeneSpring GX software package v10.0.2 and lead
to the identification of 89 genes differentially expressed in all three dietary approaches. Generation of a biological
association network evidenced several genes, such as connective tissue growth factor (Ctgf), tissue inhibitor of
metalloproteinase 1 (Timp1), galanin (Gal), synaptotagmin 1 (Syt1), growth factor receptor bound protein 2 (Grb2),
actin gamma 2 (Actg2) and smooth muscle alpha actin (Acta2), as highly interconnected nodes of the resulting
network. Gene underexpression was confirmed by Real-Time RT-PCR.
Conclusions: Ctgf, Timp1, Gal and Syt1, among others, are genes modulated by CLA supplementation that may
have a role on mucosal immune responses in early life.
Background
Food components play a role in influencing, either
directly or indirectly (through hormonal regulation), the
expression of genes encoding for proteins involved in
energy metabolism, cell differentiation and growth and
immune responses. More specifically, diet exerts diverse
effects on the development of the immune system, even
at the level of gene regulation [1]. It is known that poly-
unsaturated fatty acids (PUFAs) can modulate the
expression of a variety of genes encoding for cytokines,
adhesion molecules, and inflammatory proteins [2,3].
This fact seems to be very important during early life,
since docosahexanoic and arachidonic acids were
reported to participate in the development of the neo-
nate immune system, although their proportion among
total fatty acids in human breast milk is very low [4].
Human milk contains PUFAs such as conjugated lino-
leic acid (CLA), among others, that seem to contribute
to immune development [5-8].
CLA is a class of positional and geometric conjugated
dienoic isomers of linoleic acid, among which, cis9,
trans11 (c9,t11) predominate, accounting for 83% to
100% of total CLA present in milk [5-7], whereas
trans10,cis12 (t10,c12) exist in lower proportion [9,10].
However, it is the intake of food of ruminant origin
which determines the total concentration of CLA in
dam’s milk [7]. Many other beneficial physiological
effects have also been attributed to CLA, including
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atherosclerosis, and diabetes [11-13].
Existing data regarding the effects of CLA on the
immune system show great variability, mainly due to
differences in the animal species used, the length of the
supplementation period, and the differences in the iso-
mer mixtures used in the experimental approach. In this
direction, recent studies in suckling animals showed that
the immune function is enhanced after feeding with an
80:20 isomer mix of c9,t11 and t10,c12 CLA [14,15].
Specifically, sera IgG concentration and IgM in vitro
production by splenocytes are increased after CLA sup-
plementation during suckling. CLA downmodulatory
effects on lymphoproliferation were only observed after
an extra week of diet [16]. The immune effects of CLA
were also described in adult rats receiving this mixture
since pregnancy [17]. However, little work has been
done on the effects of CLA on gene expression, and
even less regarding the development of the immune sys-
tem in early life.
Nutritional genomics is a result of the genetic revolu-
tion experienced over the past 10 years. Nutrigenomics
deals with the interactions between dietary components
and the genome and the resulting changes in proteins
and other metabolites. On the other hand, nutrigenetics
aims to understand the gene-based differences in
response to dietary components and to develop nutra-
ceuticals that are the most compatible with the health
status of individuals based on their genetic makeup [18].
The number of successful examples of transcriptome,
proteome, and metabolome profiling as tools for evalu-
ating the cellular responses to nutrients and identifying
their molecular targets, has grown significantly. The use
of high-density microarrays is a useful approach to esti-
mate correlations among genes, which in turn can
become the basis of transcriptional networks. The avail-
ability of microarrays for a number of model systems
allows the quantification of relative transcript abun-
dances in a comprehensive fashion. Despite the rela-
tively simplistic nature of correlation measurements,
they reflect an integrative view of gene-gene interactions
in any given system, pointing out general structure char-
acteristics of transcriptional interaction networks [19].
Additionally, nutrigenomic approaches have been
undertaken to get further insight on the molecular
understanding of mechanisms triggered by nutritional
interventions. Diets enriched in different long-chain
polyunsaturated fatty acids (LC-PUFAs) have been
tested in rat nutritional intervention models. One report
revealed steaoryl-CoA desaturase as an enzyme target
for an arachidonate-enriched diet [20]. In another study,
Berger et al. [21] looked at transcriptional effects of
these LC-PUFA-enriched diets on murine hepatic and
hippocampal gene expression. Additionally, the
beneficial effect of LC-PUFAs was assessed by a nutrige-
nomics experiment designed to understand the mechan-
isms by which these lipids induce and control gene
signalling involved in carcinogenesis [22].
With all these concepts in mind and based on previous
studies, we hypothesized that CLA intake during devel-
opmental phases would exert some influencing effect,
among others, on genes involved in the regulation of the
immune system. The aim of our study was the evaluation,
by using whole genome microarrays, of the effects of
dietary supplementation with an 80:20 isomer mix of c9,
t11 and t10,c12 CLA, on mesenteric lymph nodes (MLN)
gene expression, during gestation and/or suckling. The
list of common genes differentially expressed in the three
dietary interventions was used to construct a Biological
Association Network (BAN). This approach allowed us
to obtain a global view of gene expression in MLN,
formed by a collection of nodes with different degrees of
interrelationship, that could be used to explain the mole-
cular mechanisms triggered by CLA.
Results
Effect of CLA supplementation on rat MLN gene
expression profiles
Wistar rats were subjected to a dietary supplementa-
tion during gestation and/or suckling with an 80:20
isomer mix of c9,t11 and t10,c12 CLA (Figure 1). CLA
Figure 1 Experimental design. Total period of CLA
supplementation (TPS) is shown in parentheses for each group of
animals. Pups from dams fed with 1% CLA diet during the last two
weeks of gestation and throughout the suckling period constituted
Group A. Pups from dams fed only during the last two weeks of
gestation with a 1% CLA diet and receiving CLA by daily oral
gavage throughout the suckling period represented Group B. Pups
from dams fed with a standard diet during the last two weeks of
gestation and suckling and receiving CLA by daily oral gavage
throughout the suckling period corresponded to Group C. Pups
from dams fed with a standard diet throughout the study,
constituted the reference diet group our Group D.
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Page 2 of 13transfer was confirmed at day 21, when the proportion
of CLA present in pup’s plasma was around two times
higher in groups A and B than that in group C, while
values on reference group were very low [15]. At day
21, MLN were obtained and total RNA was prepared.
The expression profile of MLN from control animals
and supplemented with CLA was determined with the
aid of the specific GeneChip
® Rat Genome 230 2.0,
which includes more than 28,000 rat genes. Data from
these microarrays were uploaded in the database repo-
sitory of Gene Expression Omnibus (GEO, [23]) and
can be accessed through series accession number
GSE23004. Upon normalization and statistical filtering
using GeneSpring GX software package v10.0.2, lists of
differentially expressed genes by 2-fold were built as
described in Methods, and presented as additional files
1, 2 and 3. CLA supplementation during gestation and
suckling (groups A and B) modulated the expression of
1332 genes whereas the dietary supplementation only
during suckling modulated the expression of 517
genes. Moreover, CLA supplementation during gesta-
tion and suckling through dam’s milk (group A)
decreased the expression of 1001 genes and up-regu-
lated 103 genes in MLN. The dietary supplementation
during gestation and suckling by oral gavage (group B)
decreased the expression of 257 genes and up-regu-
lated 371 genes, whereas supplementation only during
suckling (group C) decreased the expression of 271
genes and up-regulated 351 genes in MLN.
Identification of common genes modulated by CLA
supplementation
Venn diagrams were used to compare the lists of 2-fold
differentially expressed genes obtained for the three
experimental groups of animals (Figure 2). Lists of upre-
gulated and dowregulated genes were compared sepa-
rately in order to find the same expression patterns
between the dietary interventions compared (e.g. genes
upregulated in both). Experimental groups A and B
shared 84 upregulated and 31 downregulated genes,
groups A and C displayed 80 upregulated and 21 down-
regulated genes in common and 276 upregulated and
117 downregulated genes were found in common for
both groups B and C. A total of 89 genes were found to
be differentially expressed in all three conditions due to
CLA supplementation (76 up plus 13 down). These 89
genes are presented as Table 1. We also analyzed global
changes in gene expression independently of the type of
regulation. We observed that 34 genes displayed down-
regulation in group A (CLA transfer through milk) and
upregulation in groups B/C (CLA transfer by oral
gavage) (Data not shown). This behavior suggests a role
for the way of CLA administration in modulating gene
expression.
Detection of gene nodes upon BAN generation
A BAN was generated as described in Methods with the
list of differentially expressed genes in common among
the three groups of animals. This type of graphical
representation evidenced several genes, such as connec-
tive tissue growth factor (Ctgf), tissue inhibitor of metal-
loproteinase 1 (Timp1), galanin (Gal), synaptotagmin 1
(Syt1), growth factor receptor bound protein 2 (Grb2),
actin gamma 2 (Actg2) and smooth muscle alpha actin
(Acta2), as highly interconnected nodes of the resulting
network (Figure 3).
Validation of node-genes selected from the BAN
We proceeded to validate the differential expression of
the node-genes to verify the changes in their mRNA
levels. Real-time PCR offers a non hybridization-based
detection and was chosen as complementary to microar-
rays. The genes selected from the BAN representation
were analyzed by RT-Real time PCR under the same
experimental conditions as for the microarray analyses.
Results are shown in Figure 4, where the levels of
mRNA determined both in the microarrays and by RT-
Real Time PCR for each gene in each experimental
group are represented. In MLN, the mRNA levels for
Gal and Actg2 were decreased by around 99%, and
those of Timp1 and Syt1 decreased by 90-95% upon
CLA administration in all groups of animals tested (p <
0.001). Treatment with CLA also decreased mRNA
expression of Ctgf and Acta2 by around 80% (p < 0.01).
Grb2 showed no changes in gene expression when
determined by RT-Real Time PCR (p > 0.05, data not
shown), at variance with the data obtained from the
microarrays. These results confirmed the RNA data
obtained in the screening performed using the microar-
rays for all the selected genes with the exception of
Grb2.
Figure 2 Venn Diagram of differentially expressed genes. Venn
diagrams in GeneSpring GX were used to compare the lists of
genes differentially expressed by 2-fold (p < 0.05) in each of the
three experimental groups of animals. The diagrams show the
number of genes that belong to each of the individual lists, the
genes in common between each pair of lists and the genes in
common among all three lists (in the center of the representation)
for each type of regulation (A: Upregulation and B: Downregulation).
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Page 3 of 13Table 1 Common genes among the three experimental groups supplemented with CLA
Gene Symbol Description Gene Ontology Biological Process Ratio A Ratio B Ratio C
Actg2 actin, gamma 2, smooth muscle, enteric 70.79 D 97.48 D 105.85 D
Cnn1 calponin 1, basic, smooth muscle actin cytoskeleton organization 17.18 D 20.13 D 19.90 D
Myh11 myosin, heavy chain 11, smooth muscle smooth muscle contraction 16.49 D 16.57 D 19.68 D
Pcp4 Purkinje cell protein 4 12.37 D 12.81 D 12.94 D
Tpm2 tropomyosin 2 regulation of ATPase activity 7.89 D 7.26 D 6.84 D
Krt19 keratin 19 response to estrogen stimulus 7.78 D 5.59 D 9.12 D
Tpm1 Tropomyosin 1, alpha muscle contraction 7.38 D 8.09 D 8.27 D
Cfb complement factor B complement activation 7.11 D 4.99 D 7.82 D
Acta1 actin, alpha 1, skeletal muscle cell growth 7.10 D 7.54 D 7.18 D
Gal galanin prepropeptide inflammatory response 6.38 D 7.03 D 7.72 D
Rnase4 ribonuclease, RNase A family 4 proton transport 5.38 D 2.53 D 4.06 D
Upk1b uroplakin 1B epithelial cell differentiation 5.36 D 4.17 D 5.51 D
Rnase4 ribonuclease, RNase A family 4 proton transport 5.36 D 2.38 D 3.58 D
Mylk myosin light chain kinase 5.04 D 4.11 D 3.23 D
Tpm1 tropomyosin 1, alpha muscle contraction 4.97 D 5.34 D 5.80 D
Tnfaip6 tumor necrosis factor alpha induced 6 cell adhesion 4.94 D 3.35 D 4.39 D
Klhl23 kelch-like 23 4.62 D 2.99 D 2.93 D
Tnfrsf11b tumor necrosis factor receptor 11b signal transduction 4.37 D 2.02 D 2.46 D
Fhl1 four and a half LIM domains 1 cell differentiation 4.22 D 2.56 D 2.73 D
Synm synemin, intermediate filament protein 3.96 D 3.69 D 4.74 D
Tmem100 transmembrane protein 100 3.76 D 3.06 D 3.71 D
Smoc2 SPARC related modular calcium binding 2 cell-substrate adhesion 3.68 D 5.14 D 7.01 D
Pln phospholamban calcium ion transport 3.68 D 3.66 D 3.89 D
Tm4sf1 transmembrane 4 L six family member 1 3.61 D 2.09 D 2.35 D
Acin1 apoptotic chromatin condensation inducer 1 chromosome condensation 3.59 U 3.09 U 2.69 U
Grem2 gremlin 2, cysteine knot superfamily, homolog BMP signaling pathway 3.52 D 3.38 D 4.83 D
Pik3c2b phosphoinositide-3-kinase, class 2, beta cell communication 3.45 U 3.42 U 2.95 U
Fbxl22 F-box and leucine-rich repeat protein 22 3.36 D 3.72 D 3.67 D
Nupr1 nuclear protein 1 acute inflammatory response 3.31 D 3.00 D 3.01 D
Nov nephroblastoma overexpressed gene regulation of cell growth 3.27 D 3.10 D 3.48 D
Scg2 secretogranin II MAPKKK cascade 3.22 D 3.16 D 3.15 D
Rbm5 RNA binding motif protein 5 nuclear mRNA splicing 3.14 U 3.99 U 4.04 U
Tpm1 tropomyosin 1, alpha muscle contraction 3.11 D 3.29 D 3.27 D
Tpm1 tropomyosin 1, alpha muscle contraction 3.11 D 4.63 D 4.57 D
Bzrap1 benzodiazapine receptor associated protein 1 3.08 U 3.61 U 3.25 U
Zeb2 Zinc finger E-box binding homeobox 2 regulation of transcription 3.07 U 5.80 U 2.06 U
Adamts1 ADAM metallopeptidase with thrombospondin 1 proteolysis 3.01 D 2.26 D 2.34 D
Myl9 myosin, light chain 9, regulatory 3.01 D 5.94 D 5.54 D
Gap43 growth associated protein 43 regulation of cell growth 2.98 D 3.34 D 3.22 D
Aldh1a1 aldehyde dehydrogenase 1 family, A1 metabolic process 2.94 D 2.77 D 2.91 D
Krt8 keratin 8 apoptosis 2.93 D 3.97 D 3.54 D
Gstm5 glutathione S-transferase, mu 5 metabolic process 2.86 D 3.14 D 2.81 D
Sh3bgr SH3 domain binding glutamic acid-rich 2.85 D 3.32 D 3.40 D
Prph peripherin cytoskeleton organization 2.81 D 3.59 D 4.12 D
Ctgf connective tissue growth factor cartilage condensation 2.80 D 3.59 D 5.12 D
Sparcl1 SPARC-like 1 2.74 D 2.00 D 2.65 D
Pgm5 phosphoglucomutase 5 carbohydrate metabolism 2.74 D 3.86 D 4.72 D
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Klhl23 kelch-like 23 2.74 D 2.26 D 2.16 D
Fhl1 four and a half LIM domains 1 cell differentiation 2.73 D 2.74 D 3.13 D
Acta2 smooth muscle alpha-actin muscle contraction 2.70 D 4.63 D 2.86 D
Msln mesothelin cell adhesion 2.69 D 2.58 D 3.63 D
Sstr3 somatostatin receptor 3 signal transduction 2.67 U 3.11 U 2.90 U
Ppp1r14a protein phosphatase 1, regulatory subunit 14A phosphorylation 2.65 D 4.99 D 4.83 D
Timp1 TIMP metallopeptidase inhibitor 1 cell activation 2.64 D 4.04 D 4.54 D
Bcl2l2//Pabpn1 Bcl2-like 2//poly(A) binding protein nuclear 1 apoptosis 2.64 U 2.40 U 2.40 U
Ash1l Ash1 (absent, small, or homeotic)-like 2.58 U 3.43 U 3.85 U
Mylk myosin light chain kinase 2.57 D 3.10 D 3.94 D
Adh1 alcohol dehydrogenase 1 retinoid metabolism 2.52 D 2.52 D 2.56 D
Ptgis prostaglandin I2 synthase prostaglandin biosynthesis 2.48 D 2.92 D 3.33 D
Stmn2 stathmin-like 2 intracellular signaling 2.45 D 2.40 D 2.33 D
Gpd1 glycerol-3-phosphate dehydrogenase 1 gluconeogenesis 2.43 D 2.40 D 2.79 D
Pdlim3 PDZ and LIM domain 3 actin filament organization 2.42 D 2.33 D 2.50 D
Cgnl1 cingulin-like 1 2.41 D 2.01 D 2.15 D
Pla2g2a phospholipase A2, group IIA phospholipid metabolism 2.41 D 2.93 D 3.05 D
Ikzf2 IKAROS family zinc finger 2 2.39 U 5.10 U 4.82 U
Rgs4 regulator of G-protein signaling 4 signal transduction 2.39 D 2.27 D 2.55 D
Argbp2 Arg/Abl-interacting protein ArgBP2 intracellular signaling 2.36 D 2.30 D 2.45 D
Fgf13 fibroblast growth factor 13 MAPKKK cascade 2.35 D 2.80 D 2.86 D
Igf2 insulin-like growth factor 2 cell proliferation 2.30 D 4.82 D 6.01 D
Syt1 synaptotagmin I transport 2.29 D 2.46 D 2.30 D
Hspb1 heat shock protein 1 response to heat 2.24 D 3.69 D 5.15 D
Gja5 gap junction protein, alpha 5 cell communication 2.24 D 3.04 D 2.93 D
Schip1 schwannomin interacting protein 1 2.23 D 2.92 D 2.80 D
Efemp1 EGF-containing fibulin-like extracellular matrix 1 2.23 D 2.41 D 3.39 D
Cxcr7 chemokine (C-X-C motif) receptor 7 signal transduction 2.22 D 2.24 D 3.13 D
Phemx pan hematopoietic expression 2.21 U 2.56 U 2.61 U
Gpc3 glypican 3 regulation of growth 2.20 D 3.02 D 4.39 D
Leng8 leukocyte receptor cluster member 8 2.20 U 2.34 U 2.10 U
Crispld2 cysteine-rich secretory protein LCCL domain containing 2 lung development 2.20 D 3.82 D 3.77 D
Tagln transgelin cytoskeleton organization 2.20 D 3.49 D 3.54 D
Grb2 growth factor receptor bound protein 2 MAPKKK cascade 2.19 U 2.42 U 2.25 U
Parva parvin, alpha cell adhesion 2.16 D 2.04 D 2.30 D
Hist1h4b histone cluster 1, H4b nucleosome assembly 2.15 U 2.44 U 2.08 U
Des desmin 2.12 D 3.69 D 4.05 D
Cryab crystallin, alpha B glucose metabolic process 2.09 D 3.37 D 3.18 D
Enpp3 ectonucleotidepyrophosphatase phosphodiesterase 3 phosphate metabolism 2.05 D 2.21 D 2.52 D
Bag2 Bcl2-associated athanogene 2 apoptosis 2.04 D 3.04 D 3.12 D
Wfdc1 WAP four-disulfide core domain 1 regulation of cell growth 2.01 D 2.66 D 2.80 D
Cd9 CD9 molecule cell adhesion 2.01 D 2.24 D 2.12 D
The lists of genes differentially expressed by 2-fold with a p-value < 0.05 obtained for each experimental group were compared using Venn Diagrams in
GeneSpring GX software v 10.0.2. The table shows the list of genes differentially expressed in all three conditions, and includes the Gene Symbol for all genes,
their associated description and one of the Gene Onthology categories to which the genes belong according to GeneSpring GX. The ratio columns correspond to
the absolute fold change in expression for the genes in each experimental group (A, B or C) relative to the control group (D) and the type of regulation (U,
upregulation; D, downregulation).
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In this work, we analyzed the gene expression profile of
MLN cells from suckling rats receiving an 80:20 c9,t11:
t10,c12 CLA mix during early life. This particular mix-
ture enriched with the c9,t11 isomer was used due to its
resemblance with that in human breast milk [5]. Pre-
vious studies have demonstrated that this mix modulates
immune development in suckling rats receiving it during
gestation/suckling [15]. The main effect of this type of
diet was found regarding immunoglobulin production at
systemic and intestinal level [14,15]. However, the pre-
cise mechanism of action of this PUFA was not estab-
lished. Thus, we used microarrays to get further insight
in the effects of CLA supplementation on MLN gene
expression. A large number of genes were modulated
when CLA was administered during gestation and suck-
ling (groups A and B, 5 wk). However, the use of Venn
Diagrams evidenced that many genes were differentially
expressed in both groups B and C, and less common
genes were found between group A and the others. This
behavior could be due to the different nutritional inter-
vention that was performed. In the group A, CLA was
added to the diet of the dams during suckling period
and therefore CLA was incorporated in breast milk and
transferred to the suckling pups. However, in groups B
and C, CLA was directly administered by oral gavage to
the suckling pups. This fact influences the proportion
between the two CLA isomers that get to pups, as the
ratio of c9,t11 CLA/t10,c12 CLA in pups’sp l a s m aw a s
83:14 for group A, but 93:7 for group B and 94:6 for
group C as previously described [15].
The list of differentially expressed genes in the three
conditions was used to generate a BAN. Several node
genes, namely Ctgf, Timp1, Gal, Syt1, Actg2 and Acta2,
were selected from this BAN, and changes in their
mRNA expression were confirmed by RT-Real time
Figure 3 BAN of differentially expressed genes. The list of common genes among the three experimental groups of animals was the starting
point to construct a BAN using the Pathway Architect software within GeneSpring GX. Expanded networks were constructed by setting an
advanced filter that included the categories of binding, expression, metabolism, promoter binding, protein modification and regulation (see inset
legend). Only proteins are represented. Genes present in the original list of common genes are encircled in blue, whereas the other genes were
added by the software from the interactions database. The BAN presented shows some highly interconnected node genes that were object of
further studies (pointed with arrows).
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Page 6 of 13PCR. Some of these node-genes may explain the beha-
vior of CLA as immune modulator during early age.
Connective tissue growth factor (Ctgf) is a secreted
extracellular matrix-associated protein that modulates
many cellular functions, including proliferation, migra-
tion, adhesion, and extracellular matrix production, and
it is involved in several biological and pathological pro-
cesses [24]. Dietary supplementation with CLA reduced
mRNA levels of Ctgf in MLN in our three experimental
approaches, indicating that downregulation of Ctgf is
independent of the length and via of CLA supplementa-
tion. Ctgf is mainly regulated at the transcriptional level
by bioactive lipids, as well as TGFb and downstream
mitogen-activated protein (MAP) kinase signaling [25].
We have previously reported that young (28-day-old)
and adult animals fed with the same CLA mixture
showed a reduction in the proliferation activity of spleen
and MLN cells [16,17]. Given that Ctgf promotes DNA
synthesis in chondrocytes, osteoblasts and fibroblasts
[26], the observed decrease in proliferation could be
mediated through Ctgf downregulation.
Tissue inhibitors of metalloproteinases (Timp) are
multifunctional proteins including four members
(Timp1-4). Timp1 is expressed and secreted by a variety
of cell types and is present in most tissues [27,28].
Timp1 is able to promote cell growth, and its expression
levels inversely correlate with the susceptibility to induc-
tion of apoptosis (reviewed in [29]).
Until now, two studies have reported different effects
of CLA on Timp1 expression. On one hand, 1% CLA
diet in a mice model of metastatic mammary tumor
increased mRNA and protein levels of Timp1 [30],
whereas an in vitro study using pure CLA isomers (c9,
t11 CLA and t10,c12 CLA) on a macrophage cell line
did not modify Timp1 gene expression [31]. Thus, the
effect of CLA on Timp1 expression may depend on the
tissue microenvironment and the experimental approach
used. In our study, CLA administration reduced mRNA
levels for Timp1 in all three groups of animals. As
Timp1 may stimulate cell proliferation by using several
distinct signalling pathways, such as MAPK, the inhibi-
tory effect of CLA on this gene may reduce lymphopro-
liferation. Thus, both Timp1 and Ctgf would play a role
in a same signaling pathway that could explain the
downmodulation of the lymphoproliferative response
observed in 28-day-old animals fed with CLA from birth
[16].
The neuropeptide Galanin (Gal) was also downregu-
lated at the mRNA level by early CLA administration,
independently of length, duration and via of
Figure 4 mRNA levels of selected node genes. The mRNA levels of the indicated genes were determined for the four groups of animals by
RT-Real Time PCR as described in Methods. Empty bars represent the mRNA levels for each specific gene as determined in the microarray
experiments, filled bars represent the mRNA levels for each specific gene as determined by RT-Real Time PCR. ** p < 0.01 and *** p < 0.001.
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effects, not only in the central nervous system [32] but
also in the enteric nervous system [33]. Although Gal is
mainly produced by neurons, it has been described that
lymphocytes and macrophages can also synthesize it at a
lower level [33]. A clear effect of neuropeptides such as
somatostatin (SOM) or vasoactive intestinal peptide
(VIP), including gut-associated immune system (GALT),
has been already reported on the immune system [34].
When these neuropeptides are found in the intestine,
they seem to affect the proliferation, differentiation and
function of immune cells [33]. Thus, the effect of CLA
on Gal expression could explain the immunoenhancing
effects of CLA on developing GALT [17].
There is no data available on the effects of Gal on
lymphoproliferation. SOM and VIP are mainly inhibitors
of lymphocyte proliferation, apparently by reducing
interleukin-2 production [34], whereas calcitonin-gene-
related-peptide (CGRP), substance P (SP) or met-enke-
phalin stimulate lymphoproliferation [35,36]. Gal-
mediated effects through its receptor Galr1 led to anti-
proliferative effects, whereas those through Galr2 and
Galr3 were proliferative. All three receptors are
expressed in immune cells [37]. When the same CLA
mix was administered to young rats supplemented dur-
ing suckling [16] or until adult age [17], a downmodula-
tory activity on proliferation in both spleen and MLN
was observed, suggesting that this effect may be
mediated in part by modulation of Gal expression.
Thus, CLA is able to reduce Gal promoting activity on
lymphoproliferation, indicating that Gal would be acting
mainly through its Galr2 and Galr3 receptors in that
environment.
During early life CLA is able to enhance the production
of immunoglobulins [15] and more specifically IgA in the
intestine [14]. Enhancement of intestinal IgA concentra-
tion by CLA could be due to the decrease of Gal expres-
sion in MLN, as it is the case for SOM in murine spleen,
Peyer patches and MLN [38]. Moreover, as neuropep-
tides influence cytokine production, downregulation of
G a lb yC L Am a yb et h er e s p o n s i b l ee f f e c t o ro ft h e
changes in cytokine concentrations found in previous
studies [14,15]. However, the effect on Gal found here in
early life, and their parallel immune effects, may not be
present at older ages, since the maturation state of lym-
phocytes seem to affect the response to neuropeptides
and cytokines due to their differential neuropeptidergic
receptor expression [33]. This fact is in agreement with
the effect described for CLA on developing immune sys-
tem and immunoglobulin production [15,17], which is
not observed later in life.
Synaptotagmins (Syts) constitute a family of proteins
that act as Ca
2+-sensors for regulated exocytosis and
endocytosis [39-41]. Synaptotagmin proteins were first
detected in the nervous system, but their expression has
also been reported in other tissues. Thus, synaptotag-
mins have been proposed to be widespread regulatory
proteins that confer Ca
2+-sensitivity in a wide range of
fusion events [39]. Indeed, Syts have been described to
p l a yar o l ei nt h em a i n t e n a n c eo fp l a s m am e m b r a n e
integrity [40], in cell resealing [42], in chemotactic cell
migration [43], in insulin release from the pancreatic b-
cells [44,45], in FGF-1 secretion in response to heat
shock [46] and in degranulation of mast cells [47].
CLA supplementation caused downregulation of Syt1
by about 2.3 fold in the three dietary approaches. Syt1 is
mainly localized in synaptic vesicles, where it functions
as a Ca
2+-sensor for exocytosis [48]. Indeed, Syt1 has
been proposed to play specific roles in synaptic vesicles
trafficking, in facilitating docking [49], and in vesicle
fusion [50]. Although it has been traditionally proposed
to be a neuron-specific isoform, Syt1 has been demon-
strated to have important roles in membrane trafficking
in non-neural and non-hormonal cells [51,52].
Syt1 was previously associated with CLA supplementa-
tion, as its expression was significantly decreased in
mice receiving a diet enriched in the t10,c12 CLA iso-
mer compared with c9,t11 CLA [52]. Syt1 downregula-
tion was associated with the presence of hepatic fat,
suggesting that changes in expression of Syt1 may indi-
cate that other genes than the traditional are involved in
lipid handling in hepatic cells, and probably in MLN.
Syt1 has also been shown to play a role in neurotrans-
mitter release [53,54]. As described above, we found the
neuropeptide Gal underexpressed upon CLA supple-
mentation. Since it has been described that Gal is
secreted by enteric nerves [55], we propose that downre-
gulation of Syt1 upon CLA supplementation would lead
to a decrease in Gal secretion, thus enhancing the nega-
tive effects that downregulation of Gal would have on
lymphoproliferation.
Actins are highly conserved proteins that are involved
in various types of cell motility, and maintenance of the
cytoskeleton. In vertebrates, three main groups of actin
isoforms, alpha, beta and gamma have been identified.
The alpha actins are found in muscle tissues and are a
major constituent of the contractile apparatus. The beta
and gamma actins co-exist in most cell types as compo-
nents of the cytoskeleton, and as mediators of internal
cell motility. There are three a-actins (skeletal, cardiac,
and smooth muscle), one b-actin (b-nonmuscle), and
two g-actins (g-smooth muscle and g-nonmuscle) [56].
The cytoskeleton constitutes a network that serves to
maintain cell shape and to regulate dynamic cellular
functions. It provides essential scaffolding for the locali-
zation and activation or inhibition of diverse cytoplasmic
signaling molecules, as well as anchors for motor pro-
teins that are necessary for intracellular transport and
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Page 8 of 13cell division [57,58]. In our microarray experiments we
found that expression of smooth muscle g-actin (Actg2),
found in enteric tissues, and a2-actin (Acta2) were
decreased upon dietary supplementation with CLA.
Alpha-smooth muscle actin expression is regulated by
TGF-b and TNF-a. Changes in alpha-smooth muscle
actin, collagen, and fibronectin expression result in
decreased contraction and stiffness of collagen matrices
[59]. The effect of TGF-b has been related to a conserved
TGF-b control element (TCE) within the 5’-region of
alpha-smooth muscle actin, also known as smooth mus-
cle cell differentiation marker. TCE could mediate both
transcriptional activation and repression in cultured
smooth muscle cells through interaction with members
of the zinc finger Kruppel-like transcription factor family
[60]. On the other hand, it has been reported that TGF-
b1 is able to significantly increase Acta2 expression in
both normal and cancer associated fibroblasts cultures
[61], which are believed to promote tumor growth and
progression. Overall, the downregulation of actins upon
CLA supplementation would affect both the contractile
apparatus and the cytoskeleton with a final effect on cell
motility. However its relationship with the development
of the immune system remains unclear. Deficiencies in
proteins that regulate the cortical actin cytoskeleton have
increasingly been associated with immunodeficiency and
autoimmune or autoinflammatory disease, indicating a
critical role for these regulators in immune response and
tolerance (reviewed in [56]).
Besides the modulatory action of CLA found on the
above node genes, other genes with importance on the
immune system were differentially modulated and
would require further studies. This is the case of for the
receptors for interleukin-7 (Il7r) and chemokines (i.e.
Cxcr7) which are involved in mucosal immune
responses and chemotaxis, respectively [62,63].
Conclusions
In summary, by using rat whole genome microarrays, we
determined the changes in gene expression induced by
an 80:20 c9,t11:t10,c12 CLA mix in MLN from suckling
rats. The generation of a biological association network
allowed the identification of specific node genes that
might be involved in immune responses. We conclude
that Ctgf, Timp1, Gal and Syt1, among others, are gene
target candidates modulated by CLA which may explain
the effect of this PUFA on mucosal immune responses
in early life.
Methods
Animals
Wistar rats at 7 days of gestation were obtained from
Harlan (Barcelona, Spain) and housed in individual
cages under conditions of controlled temperature and
humidity in a 12 h:12 h light:dark cycle, with access to
food and water ad libitum. The rats were monitored
daily and allowed to deliver at term. The day of birth
was reported as day 1. Pups, unified in litters of ten per
lactating dam, had free access to the nipples and rat
diet. Animals were daily identified and weighed, and
handling was done in the same time range to avoid the
influence of biological rhythms. On day 21 (weaning
day), pups were anaesthetized with ketamine/xylazine
(ketamine 90 mg/kg plus xylacine 10 mg/kg of rat
weight) and sacrificed by humanitarian methods. MLN
were obtained and were flash-frozen in liquid N2 and
stored immediately at -80°C until processing. Studies
were performed in accordance with the institutional
guidelines for the care and use of laboratory animals
established by the Ethical Committee for Animal Experi-
mentation of the University of Barcelona and approved
by the Catalonian Government (CEEA 303/05, UB/
DMA 3242).
Experimental Design
Animals were randomly distributed in 4 dietary groups,
according to total period of CLA supplementation and
administration route used in the pups [15]. Total period
of CLA supplementation (TPS) is shown in parentheses
in the experimental design (Figure 1). Pups from dams
fed with a 1% CLA diet during the two last weeks of
gestation and throughout the suckling period consti-
tuted Group A. These pups received CLA through the
dam’s milk during suckling (TPS 5 wk). Pups from
dams fed only during gestation (two last weeks) with a
1% CLA diet and receiving a daily CLA supplement by
oral gavage throughout the suckling period (TPS 5 wk)
constituted group B. Pups from dams fed with a stan-
dard diet during the two last weeks of gestation and
suckling and receiving CLA by daily oral gavage
throughout the suckling period (TPS 3 wk) constituted
Group C. Group D, pups from dams fed standard diet
throughout the study, constituted the reference diet
group (TPS 0 wk).
In this later group, CLA levels present in milk samples
were very low for the c9,t11-CLA isomer (0.02 ± 0.00%
in total milk fatty acids) and undetectable for the t10,
c12-CLA isomer [15].
Dietary CLA supplementation
T h es t a n d a r dd i e tc o r r e s p o n d e dt ot h eA m e r i c a nI n s t i -
tute of Nutrition (AIN)-93G formulation [64], contain-
ing 7% soybean oil. A 1% CLA diet was obtained from
modified standard flour AIN-513 (Harlan) containing 10
g CLA/kg as previously described [14]. Thus, the sup-
plemented diet contained 6% soybean oil plus 1% CLA
oil. The CLA isomer mixture used was 80% c9,t11 and
20% t10,c12 from the total CLA isomers in oil. The 1%
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administration of 1.5 mg CLA oil provided/g rat from
day 1 to 21. Low-capacity syringes (Hamilton Bonaduz
AG) adapted to oral 25- or 23-gauge gavage tubes, 27
mm in length (ASICO) were used for oral administra-
tion before and after day 5, respectively. To allow gastric
emptying, litters were separated from dams 1 h before
oral supplementation [65]. CLA arrival to pups was con-
firmed by its quantification in 21-day-old plasma; more-
over, immunomodulatory action of CLA in these
animals by means of evaluation of sera Ig concentration,
and in vitro Ig production and proliferation by isolated
splenocytes was also previously observed [15].
RNA extraction
Three animals were randomly selected from the 10 that
constituted each experimental group. Total RNA from
MLN of each animal was prepared using the RNAeasy
Lipid Tissue Mini kit (Qiagen) following the recommen-
dations of the manufacturer. Briefly, tissue samples were
thawed and homogenized in QIAzol Lysis Reagent.
After addition of chloroform, the homogenate was sepa-
rated into aqueous and organic phases by centrifugation.
The aqueous phase was applied to the RNeasy spin col-
umn and RNA was eluted in RNase-free water. An addi-
tional step of phenol-chloroform extraction and ethanol
precipitation was performed to ensure the purity of the
RNA samples from MLN. Ribosomal RNA band integ-
rity was assessed on an Agilent BioAnalyzer 2100 using
an RNA Nano LabChip (Agilent Technologies).
Microarrays
Gene expression was determined by hybridization to the
GeneChip
® Rat Genome 230 2.0 (Affymettrix), that
allows the simultaneous analysis of the expression level
of over 30,000 transcripts and variants from over 28,000
well-substantiated rat genes. Labeling, hybridization and
detection were carried out following the manufacturer’s
specifications. Triplicate samples were hybridized for
each experimental condition.
Microarray data analysis
Gene expression analysis was carried out with Gene-
Spring GX v10.0.2 software (Agilent Technologies),
using the latest gene annotations available. This software
package allows multifilter comparisons using data from
different experiments to perform the normalization, gen-
eration of restriction lists and the functional classifica-
tion of the differentially expressed genes. All the
samples were normalized against the median of the con-
trol samples (Group D). The expression of each gene is
reported as the ratio of the value obtained after each
condition relative to control condition after normaliza-
tion of the data. Lists of differentially expressed genes
were generated using data from the three independent
experiments for each condition. A first filter was applied
to select the genes that displayed a p-value of less than
0.05. The output of this analysis was then filtered by
fold expression, generating lists of differentially
expressed genes by 2-fold for each of the experimental
groups. These lists were split in two others of upregu-
lated or downregulated genes. Comparisons of the lists
of upregulated genes among them were performed by
Venn Diagrams in GeneSpring GX. Lists of downregu-
lated genes were also compared among them using the
same approach. This procedure allowed us to find dif-
ferentially expressed genes that followed the same pat-
tern (e.g. upregulated or downregulated) in common
among the experimental conditions.
Biological Association Networks generation
The list of common genes differentially expressed by 2-
fold with a p-value < 0.05 in the tree groups of animals
was used to construct a biological association network
(BAN) using the Pathway Architect software integrated
within GeneSpring GX. Briefly, the Pathway Architect
software generates interaction networks starting with
the genes in a given list (entities) taking into account
the information present in a database of known molecu-
lar interactions. The lists correspond to the collection of
differentially expressed genes under specific conditions.
The database of molecular interactions is composed by
more than 1.6 million interactions divided into different
classes (binding, regulation, promoter binding, transport,
metabolism, protein metabolism and expression). The
interactions are extracted from literature using a Natural
Language Processing tool run on Medline Abstracts
(NLP references), plus those obtained from external
curated databases like BIND [66] and MINT [67]. Inter-
actions in the interaction database are scored into 5 dif-
ferent categories: maximum, high, medium, low and
minimal. Curated interactions (BIND and MINT
sources) get the Maximum quality score as do any inter-
actions which have at least 3 NLP references. Pathway
Architect gathers all that information to construct novel
views as to how the entities in a list could be interacting
with each other, even including entities not present in
the original list (neighbors resulting from the expanded
interaction). Customized analyses were performed to
select relevance interaction networks with an associated
high confidence index since such networks are likely to
mirror biological significance. One-step expansion
(expand network) of the original set of entities with
maximum score interaction were then analyzed by set-
ting an advanced filter that included the categories of
binding, expression, metabolism, promoter binding, pro-
tein modification and regulation. This procedure gives a
final view formed by a collection of nodes with different
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Page 10 of 13degrees of interrelationship. A number of gene products
from the original list that were not significantly con-
nected with the other members or neighbors were
removed from the final view.
RT-Real Time PCR
cDNA was synthesized in a total volume of 20 μlb y
mixing 1 μg of total RNA, 125 ng of random hexamers
(BioTools), in the presence of 75 mM KCl, 3 mM
MgCl2, 10 mM dithiothreitol, 20 units of RNAsin (Pro-
mega), 0.5 mM dNTPs (BioTools), 200 units of M-MLV
reverse transcriptase (Invitrogen) and 50 mM Tris-HCl
buffer, pH 8.3. The reaction mixture was incubated at
37°C for 60 min. The cDNA product was used for sub-
sequent amplification by Real Time-PCR. The expres-
sion levels of outlier genes differentially expressed in the
microarrays was determined in an ABI Prism 7000
Sequence Detection System (Applied Biosystems) using
3 μl of the cDNA mixture and the Assays-on-demand
Rn00583681_m1 for Gal, Rn00587558_m1 for Timp1,
Rn00573960_g1 for Ctgf, Rn00578230_m1 for Grb2,
Rn00436862_m1 for Syt1, Rn00563662_m1 for Actg2,
Rn01759928_g1 for Acta2 and Rn01432775_m1 for Aprt
(all from Applied Biosystems). Aprt mRNA was used as
an endogenous control. The reaction was performed fol-
lowing the manufacturers recommendations. Fold-
changes in gene expression were calculated using the
standard ΔΔCt method.
Additional material
Additional file 1: List of genes differentially expressed by 2-fold in
experimental Group A (CLA supplementation during gestation and
during suckling through dam’s milk). Excel file containing the list of 2-
fold differentially expressed genes in group A with respect to the control
(Group D) generated using GeneSpring software. It includes the gene
symbol of all genes and the associated description. The absolute fold
change values relative to the control group and the type of regulation
(Up or Down) are provided. The differentially expressed transcripts
corresponding to open reading frames, transcribed sequences, cDNA
clones or hypothetical genes were removed.
Additional file 2: List of genes differentially expressed by 2-fold in
experimental Group B (CLA supplementation during gestation and
during suckling through oral gavage). Excel file containing the list of
2-fold differentially expressed genes in group B with respect to the
control generated as described in Additional file 1.
Additional file 3: List of genes differentially expressed by 2-fold in
experimental Group C (CLA supplementation during suckling
through oral gavage). Excel file containing the list of 2-fold differentially
expressed genes in group C with respect to the control generated as
described in Additional file 1.
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